Pluri Inc.
PLUR · NASDAQ
Market closed$1.86$0.060000 (+3.33%)After hours $1.86 · 0.00%
Key statistics
Previous close$1.80
Open$1.86
Day high$2.01
Day low$1.82
52-week high$5.68
52-week low$1.56
Market cap16.72M
Volume37.33K
Average volume22.51K
P/E ratio-0.41
Forward P/E—
EPS-4.53
Dividend yield0.00%
Market context
Why it moved
PLUR edged higher despite a broader market risk-off selloff driven by chip stock fatigue, AI spending concerns, and flaring Middle East tensions, suggesting the stock benefited from rotation into smaller, non-semiconductor names as investors stepped back from overcrowded AI-related positions.
What is happening
Recent company-specific developments and publisher coverage.
CTech · July 16, 2026Once worth NIS 1 billion, Pluri is now racing to avoid Nasdaq delistingStock Titan · July 14, 2026Pluri Chairman Builds 30%-Plus Position With $17M InvestmentTradingView · July 13, 2026Pluri Disclosed Failure to Satisfy a Continued Listing Rule or StandardInvesting.com · June 1, 2026Pluri Inc. and European Investment Bank continue loan discussions, no enforcement action expected before JulyContract Pharma · February 18, 2026Pluri Biotech Secures China Patent for Immune Cell Techi24NEWS · February 17, 2026Pluri's Cell Therapy To Extends Lifespan And Combat Chronic Disease Benzinga · July 14, 2026Pluri Announces Chairman Alejandro Weinstein Has Invested $17M+In PLUR, Including A $1.25M Advance Investment Made In June 2026 Benzinga · June 2, 2026Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch Benzinga · February 18, 2026Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech Benzinga · February 12, 2026Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate Benzinga · January 22, 2026Pluri Completes First Phase Of Its Program With Resbiomed Technologies OOD Over Placenta-Derived Processing, Bioprocessing Capabilities Benzinga · December 22, 2025Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production Benzinga · December 9, 2025Pluri Appoints Alejandro Weinstein As Chairman